The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Inhibikase Therapeutics Inc shares valued at $2,000,200 were purchased by Bellini Roberto on Oct 21 ’24. At $1.37 per share, Bellini Roberto acquired 1,460,000 shares. The insider’s holdings grew to 1,460,000 shares worth approximately $2.77 million following the completion of this transaction.
Also, Kush Arvind purchased 145,000 shares, netting a total of over 198,650 in proceeds. Following the buying of shares at $1.37 each, the insider now holds 145,000 shares.
Before that, Munshi Amit had added 365,000 shares to its account. In a trade valued at $500,050, the Director bought Inhibikase Therapeutics Inc shares for $1.37 each. Upon closing the transaction, the insider’s holdings increased to 365,000 shares, worth approximately $0.69 million.
As published in a research note from H.C. Wainwright on February 12, 2025, Inhibikase Therapeutics Inc [IKT] has been rated down from a Buy to a Neutral.
Analyzing IKT Stock Performance
During the last five days, there has been a surge of approximately 2.15%. Over the course of the year, Inhibikase Therapeutics Inc shares have dropped approximately -41.54%. Shares of the company reached a 52-week high of $3.4900 on 01/02/25 and a 52-week low of $1.5400 on 04/07/25. A 50-day SMA is recorded $2.2537, while a 200-day SMA reached $2.0991.
Support And Resistance Levels for Inhibikase Therapeutics Inc (IKT)
According to the 24-hour chart, there is a support level at 1.8333, which, if violated, would cause prices to drop to 1.7667. In the upper region, resistance lies at 1.9733. The next price resistance is at 2.0467. RSI (Relative Strength Index) is 42.84 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.0173, which suggests the price will decrease in the coming days. Percent R is at 54.43%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
